Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-

Slides:

Advertisements

Similar presentations

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Advertisements

Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma Baldeep Wirk, Timothy S. Fenske,

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies Marcelo C. Pasquini,

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis Sonali.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Allogeneic Hematopoietic Cell Transplantation for Advanced Polycythemia Vera and Essential Thrombocythemia Karen K. Ballen, Ann E. Woolfrey, Xiaochun.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome Philippe Armand,

HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced- Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from.

Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Nelli Bejanyan, Brian J.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani,

Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Marcelo C. Pasquini, Mei-Jie Zhang, Bruno C

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia Reinhold Munker, Ruta Brazauskas, Hai Lin Wang, Marcos.

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia Hien K. Duong, MD, Mojtaba Akhtari, MD, Kwang Woo Ahn, PhD, Zhen-Huan.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the.

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen–Identical Sibling Transplantations for Chronic Lymphocytic.

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival Brian L. McClune, Kwang Woo Ahn, Hai-Lin.

Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation.

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma:

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Unresponsive Mantle Cell Lymphoma: A Cohort Analysis from the Center for International.

High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation Rachel B. Salit, Filippo.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Equivalent Survival for Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia John Moore, Ian Nivison-Smith,

Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia by Saurabh Chhabra, Kwang Woo.

Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study Simrit Parmar,

Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation Abraham S. Kanate, Parameswaran.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning.

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, Julie Aldridge,

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Presentation transcript:

Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced- Intensity Conditioning Regimens Ronald M. Sobecks, Jose F. Leis, Robert Peter Gale, Kwang Woo Ahn, Xiaochun Zhu, Mitchell Sabloff, Marcos de Lima, Jennifer R. Brown, Yoshihiro Inamoto, Gregory A. Hale, Mahmoud D. Aljurf, Rammurti T. Kamble, Jack W. Hsu, Steven Z. Pavletic, Baldeep Wirk, Matthew D. Seftel, Ian D. Lewis, Edwin P. Alyea, Jorge Cortes, Matt E. Kalaycio, Richard T. Maziarz, Wael Saber Biology of Blood and Marrow Transplantation Volume 20, Issue 9, Pages 1390-1398 (September 2014) DOI: 10.1016/j.bbmt.2014.05.020 Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence curves comparing (A) grades II to IV and (B) grades III to IV acute GVHD, (C) chronic GVHD, (D) progression/relapse, and (E) TRM between MA and RIC allogeneic HCT for CLL. Biology of Blood and Marrow Transplantation 2014 20, 1390-1398DOI: (10.1016/j.bbmt.2014.05.020) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Comparison of progression-free survival between MA and RIC allogeneic HCT for CLL. (A) Performed in 2000 or earlier. (B) Performed after 2000. Biology of Blood and Marrow Transplantation 2014 20, 1390-1398DOI: (10.1016/j.bbmt.2014.05.020) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Comparison of overall survival between MA and RIC allogeneic HCT for CLL. (A) Performed in 2000 or earlier. (B) Performed after 2000. Biology of Blood and Marrow Transplantation 2014 20, 1390-1398DOI: (10.1016/j.bbmt.2014.05.020) Copyright © 2014 American Society for Blood and Marrow Transplantation Terms and Conditions